EC authorises ribociclib for advanced breast cancer

The breast cancer therapy ribociclib (Kisqali) has now been authorised by European Commission for the treatment of advanced breast cancer. It has been licensed for use in the EU as a first-line treatment for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative …

More details...

Tivozanib approved in the EU for advanced renal cell carcinoma

The European Commission has approved tivozanib (Fotivda) for the treatment of adults with advanced renal cell carcinoma within the EU.
Tivozanib is an orally active tyrosine kinase inhibitor that acts by blocking all three types of vascular endothelial growth factor receptor (VEGFR 1, 2 and 3), …

More details...

Women remain uninformed of the risks of sodium valproate

In a recent survey, conducted by the three leading epilepsy charities – Epilepsy Action, Epilepsy Society and Young Epilepsy – more than a quarter (28%) of women taking sodium valproate said that they had not received any information on the harm it could do to …

More details...

Cladribine granted licence in the UK and Ireland

Cladribine (Mavenclad) has been licensed in the UK and Ireland for the treatment of adult patients with highly active and relapsing multiple sclerosis (MS). This follows a positive decision by the European Commission in August 2017, which recommended cladribine for marketing authorisation.
“This is an exciting …

More details...

NICE approves dimethyl fumarate for plaque psoriasis

In final technology appraisal guidance (TA475), NICE has recommended dimethyl fumarate (Skilarence) as an option for the treatment of plaque psoriasis in adults.
NICE recommends treatment with dimethyl fumarate only if the disease is severe and has not responded to other systemic therapies, including ciclosporin, methotrexate …

More details...

NICE publishes first guideline on endometriosis

NICE has published its first guideline on the diagnosis and management of endometriosis (NG73). The guideline aims to raise awareness of the symptoms of endometriosis, as well as provide advice on the action to take when patients with suspected endometriosis first present in healthcare settings. …

More details...

NHS England expands international recruitment of GPs

NHS England has announced a major increase to the GP workforce through the introduction of an international recruitment programme, following a series of successful regional pilots.
 NHS England plans to recruit approximately 600 overseas doctors into general practice over the next year, increasing to at least …

More details...

Rivaroxaban can reduce the risk of cardiovascular death and stroke

The anticoagulant drug rivaroxaban (Xarelto) can significantly reduce the risk of cardiovascular death and stroke when used in combination with aspirin as the secondary prevention after a coronary event, according to new trial data announced at the European Society of Cardiology Congress, and published in …

More details...

New osteoporosis guidance means thousands more could receive drugs

Updated NICE guidelines on osteoporosis recommend that the initiation of treatment should be linked to the person’s risk of developing a bone fracture, dependent on cost-effectiveness.
Professor Carole Longson MBE, director of the centre for health technology evaluation at NICE, said: “It will provide clarity for …

More details...

New anti-inflammation drug cuts risk of heart disease

The anti-inflammatory drug canakinumab can reduce the risk of repeat heart attacks and other acute coronary events, claims the results of a four-year trial published in The New England Journal of Medicine.
Dr Paul Ridker, lead author of the study, said:  “This has far-reaching implications. It …

More details...

Web design and marketing agency Leamington Spa